Long-Term Outcomes of Patients With <i>BRCA+</i> or <i>PALB2+</i> Pancreatic Cancer Treated With Maintenance Rucaparib
This secondary analysis of a nonrandomized clinical trial assesses long-term survival and genomic variants associated with therapeutic resistance in patients receiving maintenance rucaparib with BRCA1 , BRCA2 or PALB2 germline or somatic pathogenic variants and platinum-sensitive metastatic pancreatic adenocarcinoma.
Authors
- Kim A. Reiss (ORCID: https://orcid.org/0000-0003-0774-9914)
- Ursina Teitelbaum
- C Lord
- Brad Wubbenhorst
- Mwangala P. Akamandisa
- Stephen J. Pettitt (ORCID: https://orcid.org/0000-0003-3313-3857)
- Charles Schneider
- Rashmi Tondon
- Mingyi Xia
- T D Brown
- Zain Hannan
- Kurt D’Andrea
- Andrew N J Tutt
- Ryan Hood
- Katherine L Nathanson
- Mark H O'Hara
- Susan M Domchek
- Robert H Vonderheide
Institutions
- Main Line Health (US)
- University City Science Center (US)
- Institute of Cancer Research (GB)
- University of Miami (US)
- Breast Cancer Now (GB)
- Yale University (US)
- Translational Therapeutics (United States) (US)
- University of Pennsylvania Health System (US)
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2026-04-30
- DOI
- https://doi.org/10.1001/jamaoncol.2026.0870
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00